We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

POINT Biopharma Global Inc (PNT) USD0.0001

Sell:$6.25 Buy:$7.28 Change: $0.47 (6.90%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$6.25
Buy:$7.28
Change: $0.47 (6.90%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$6.25
Buy:$7.28
Change: $0.47 (6.90%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company, through its subsidiaries is focused on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's clinical-stage product candidates include PNT2003 and PNT2002 for the treatment of prostate cancer and neuroendocrine tumors. Its preclinical stage product candidates include Lu-PNT2004 and Lu-PNT2001. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2004 is a family of fibroblast activation protein-alpha (FAP-alpha), which targeted radioligands. PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors.

Contact details

Address:
4850 West 78Th Street, 18Th Floor
INDIANAPOLIS
46268
United States
Telephone:
+1 (317) 5439957

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PNT
ISIN:
US7305411099
Market cap:
$593.92 million
Shares in issue:
90.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.